These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29908284)

  • 21. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis.
    Lee H; Lee YJ; Choi H; Seok JW; Yoon BK; Kim D; Han JY; Lee Y; Kim HJ; Kim JW
    Sci Rep; 2017 Nov; 7(1):14833. PubMed ID: 29093466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway.
    Wen X; Wang N; Zhang F; Dong C
    Mol Med Rep; 2016 Mar; 13(3):2885-91. PubMed ID: 26847210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
    Rasti M; Tavasoli P; Monabati A; Entezam M
    Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
    Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
    Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPER Promoter Methylation Controls GPER Expression in Breast Cancer Patients.
    Weissenborn C; Ignatov T; Nass N; Kalinski T; Dan Costa S; Zenclussen AC; Ignatov A
    Cancer Invest; 2017 Feb; 35(2):100-107. PubMed ID: 28118074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RhoBTB2 gene in breast cancer is silenced by promoter methylation.
    Tang W; Wang C; Fu F; Chen Q
    Int J Mol Med; 2014 Mar; 33(3):722-8. PubMed ID: 24356943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
    Pirouzpanah S; Taleban FA; Mehdipour P; Atri M
    J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant CBFA2T3B gene promoter methylation in breast tumors.
    Bais AJ; Gardner AE; McKenzie OL; Callen DF; Sutherland GR; Kremmidiotis G
    Mol Cancer; 2004 Aug; 3():22. PubMed ID: 15301688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation.
    Janostiak R; Vyas M; Cicek AF; Wajapeyee N; Harigopal M
    Exp Mol Pathol; 2018 Aug; 105(1):41-49. PubMed ID: 29852185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
    Ai L; Tao Q; Zhong S; Fields CR; Kim WJ; Lee MW; Cui Y; Brown KD; Robertson KD
    Carcinogenesis; 2006 Jul; 27(7):1341-8. PubMed ID: 16501252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
    Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
    Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
    Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.
    De Souza Santos E; De Bessa SA; Netto MM; Nagai MA
    Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.